Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 0.67 |
| ▸ | HTR3A | P46098 | 5/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | HTR7 | P34969 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218837 | 1.00 | ADRB1 (1.00) | ADRB1HTR1AHTR3ACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL27850954 | 0.98 | ADRB1 (0.96) | ADRB1HTR1AHTR3ACYP1A2CYP2D6 | |
| Piperazine SCHEMBL27593403 | 0.98 | ADRB1 (0.96) | ADRB1HTR1AHTR3ACYP1A2CYP2D6 | |
| Iodide SCHEMBL11457680 | 0.98 | ADRB1 (0.96) | ADRB1HTR1AHTR3ACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL1894847 | 0.98 | ADRB1 (0.96) | ADRB1HTR1AHTR3ACYP1A2CYP2D6 | |
| SCHEMBL9310335 | 0.93 | ADRB1 (0.87) | ADRB1HTR1AHTR3ACYP1A2CYP2D6 | |
| SCHEMBL7487422 | 0.90 | ADRB1 (0.81) | ADRB1HTR1AHTR3ACYP1A2CYP2D6 | |
| SCHEMBL27868178 | 0.90 | ADRB1 (0.81) | ADRB1HTR1AHTR3ACYP1A2CYP2D6 | |
| SCHEMBL11067105 | 0.86 | ADRB1 (0.74) | ADRB1ALDH1A1NPSR1TSHRMAPK1 | |
| SCHEMBL7979300 | 0.85 | ADRB1 (0.74) | ADRB1HTR1AHTR3ACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112831206-B | Inorganic oxide dispersion with controllable water content and preparation method thereof | 凯斯科技股份有限公司 | 2022-12-30 | — | — | CN | claimed |
| WO-2026102161-A1 | METHODS OF TREATING OVARIAN AND PANCREATIC CANCER | CONCARLO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4712963-A2 | SMALL MOLECULE INHIBITORS OF P27 | Concarlo Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238709-A2 | SMALL MOLECULE INHIBITORS OF P27 | CONCARLO THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-112204017-B | Benzisoxazole compounds | 国立大学法人大阪大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-117769545-A | Tri-fused ring derivative-containing regulator, preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4247895-A1 | POLY ACRYLATE AND POLY(BETA-ESTER) CAPSULES WITH ENHANCED DEGRADABILITY | Encapsys, LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| CN-112831206-B | Inorganic oxide dispersion with controllable water content and preparation method thereof | 凯斯科技股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115397818-A | Aminopyrimidine derivatives and their use as modulators of arene receptors | 东亚ST株式会社 | 2022-11-25 | — | — | CN | disclosed |
| WO-2022109112-A1 | POLY ACRYLATE AND POLY(BETA-ESTER) CAPSULES WITH ENHANCED DEGRADABILITY | ENCAPSYS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | ADRB1 3478/4885HTR1A 1316/4885HTR3A 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.